WO2004103288A3 - Procede de prevention des avortements spontanes - Google Patents

Procede de prevention des avortements spontanes Download PDF

Info

Publication number
WO2004103288A3
WO2004103288A3 PCT/US2004/015040 US2004015040W WO2004103288A3 WO 2004103288 A3 WO2004103288 A3 WO 2004103288A3 US 2004015040 W US2004015040 W US 2004015040W WO 2004103288 A3 WO2004103288 A3 WO 2004103288A3
Authority
WO
WIPO (PCT)
Prior art keywords
miscarriages
methods
risk
therapeutic agent
antibody against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/015040
Other languages
English (en)
Other versions
WO2004103288A2 (fr
Inventor
Jane E Salmon
Guillermina Girardi
V Michael Holers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
New York Society for Relief of Ruptured and Crippled
Original Assignee
University of Colorado Boulder
New York Society for Relief of Ruptured and Crippled
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, New York Society for Relief of Ruptured and Crippled filed Critical University of Colorado Boulder
Priority to US10/556,493 priority Critical patent/US20070123466A1/en
Publication of WO2004103288A2 publication Critical patent/WO2004103288A2/fr
Priority to PL05722948T priority patent/PL1713503T3/pl
Priority to PT57229486T priority patent/PT1713503E/pt
Priority to PCT/US2005/004346 priority patent/WO2005077417A1/fr
Priority to EP05722948.6A priority patent/EP1713503B1/fr
Priority to ES05722948T priority patent/ES2432112T3/es
Priority to AU2005212369A priority patent/AU2005212369B2/en
Priority to BRPI0506629-8A priority patent/BRPI0506629A/pt
Priority to DK05722948.6T priority patent/DK1713503T3/da
Priority to CA2561531A priority patent/CA2561531C/fr
Priority to SI200531781T priority patent/SI1713503T1/sl
Priority to CN200580011963.0A priority patent/CN101022828B/zh
Priority to JP2006553251A priority patent/JP5137053B2/ja
Priority to US11/057,047 priority patent/US7999082B2/en
Priority to EP10188613A priority patent/EP2340850A1/fr
Publication of WO2004103288A3 publication Critical patent/WO2004103288A3/fr
Anticipated expiration legal-status Critical
Priority to US11/888,997 priority patent/US8652475B2/en
Priority to US11/843,617 priority patent/US8703140B2/en
Priority to US14/183,213 priority patent/US20140154307A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés qui permettent de traiter et prévenir les avortements spontanés, ou de réduire le risque d'avortement spontané, en particulier les avortements spontanés à répétition. Les procédés de l'invention consistent à administrer à un sujet femelle un agent thérapeutique qui module l'activité ou la liaison de composants du système complémentaire, avec un excipient pharmaceutiquement acceptable. Par exemple, l'agent thérapeutique peut être un inhibiteur de la C3-convertase, un anticorps dirigé contre C5, un antagoniste du récepteur C5a, ou un anticorps dirigé contre le facteur B ou le facteur D. L'invention se rapporte également à des procédés de criblage d'agents capables de prévenir les avortements spontanés ou réduire le risque d'avortement spontané, en particulier d'avortements spontanés à répétition.
PCT/US2004/015040 2003-05-13 2004-05-13 Procede de prevention des avortements spontanes Ceased WO2004103288A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
US10/556,493 US20070123466A1 (en) 2003-05-13 2004-05-13 Method of treating recurrent miscarriages
EP10188613A EP2340850A1 (fr) 2004-02-10 2005-02-10 Inhibition du facteur B et de la voie du complément alternative et procédés associés
DK05722948.6T DK1713503T3 (da) 2004-02-10 2005-02-10 Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
SI200531781T SI1713503T1 (sl) 2004-02-10 2005-02-10 Inhibicija faktorja B, alternativna komplementa pot in relevantni postopki
PCT/US2005/004346 WO2005077417A1 (fr) 2004-02-10 2005-02-10 Inhibition du facteur b et de la voie du complement alternative et procedes associes
EP05722948.6A EP1713503B1 (fr) 2004-02-10 2005-02-10 Inhibition du facteur b et de la voie du complement alternative et procedes associes
ES05722948T ES2432112T3 (es) 2004-02-10 2005-02-10 Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
AU2005212369A AU2005212369B2 (en) 2004-02-10 2005-02-10 Inhibition of factor B, the alternative complement pathway and methods related thereto
BRPI0506629-8A BRPI0506629A (pt) 2004-02-10 2005-02-10 inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
PL05722948T PL1713503T3 (pl) 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
CA2561531A CA2561531C (fr) 2004-02-10 2005-02-10 Inhibition du facteur b et de la voie du complement alternative et procedes associes
PT57229486T PT1713503E (pt) 2004-02-10 2005-02-10 Inibição do factor b, a via alternativa do complemento e métodos relacionados
CN200580011963.0A CN101022828B (zh) 2004-02-10 2005-02-10 B因子、补体旁路的抑制及与此相关的方法
JP2006553251A JP5137053B2 (ja) 2004-02-10 2005-02-10 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
US11/057,047 US7999082B2 (en) 2004-02-10 2005-02-10 Anti-factor B antibodies
US11/888,997 US8652475B2 (en) 2004-02-10 2007-08-03 Inhibition of factor B, the alternative complement pathway and methods related thereto
US11/843,617 US8703140B2 (en) 2004-02-10 2007-08-22 Inhibition of factor B, the alternative complement pathway and methods related thereto
US14/183,213 US20140154307A1 (en) 2004-02-10 2014-02-18 Inhibition of factor b, the alternative complement pathway and methods related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47044403P 2003-05-13 2003-05-13
US60/470,444 2003-05-13

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/057,047 Continuation-In-Part US7999082B2 (en) 2004-02-10 2005-02-10 Anti-factor B antibodies
US11/888,997 Continuation-In-Part US8652475B2 (en) 2004-02-10 2007-08-03 Inhibition of factor B, the alternative complement pathway and methods related thereto
US11/843,617 Continuation-In-Part US8703140B2 (en) 2004-02-10 2007-08-22 Inhibition of factor B, the alternative complement pathway and methods related thereto

Publications (2)

Publication Number Publication Date
WO2004103288A2 WO2004103288A2 (fr) 2004-12-02
WO2004103288A3 true WO2004103288A3 (fr) 2005-06-09

Family

ID=33476707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015040 Ceased WO2004103288A2 (fr) 2003-05-13 2004-05-13 Procede de prevention des avortements spontanes

Country Status (2)

Country Link
US (1) US20070123466A1 (fr)
WO (1) WO2004103288A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US7964705B2 (en) 2007-03-14 2011-06-21 Taligen Therapeutics, Inc. Humaneered anti-factor B antibody
US8007804B2 (en) 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US8465737B2 (en) 2001-04-11 2013-06-18 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US8652475B2 (en) 2004-02-10 2014-02-18 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713503B1 (fr) * 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition du facteur b et de la voie du complement alternative et procedes associes
US8911733B2 (en) 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
AU2006338560A1 (en) * 2005-10-21 2007-08-30 Genentech, Inc. Treatment for antiphospholipid-syndrome-related pregnancy complications
CA2704973A1 (fr) * 2007-11-08 2009-05-14 Genentech, Inc. Anticorps anti-facteur b et leurs utilisations
US7846678B2 (en) * 2008-08-18 2010-12-07 BioDtech, Inc. Enhancing endotoxin detection
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (fr) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Traitement de l'hémoglobinurie paroxystique nocturne
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
EP2681328A4 (fr) 2011-02-28 2014-10-29 Biodtech Inc Détection améliorée des endotoxines
US8691513B2 (en) 2011-06-23 2014-04-08 Quidel Corporation Methods of use for an immunoassay detecting fragment Ba
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
JP6666250B2 (ja) * 2013-09-13 2020-03-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体ｂ因子の調節薬
US10280423B2 (en) 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
WO2016151558A1 (fr) * 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. Procédé permettant de mesurer l'activité protéasique du facteur d de la voie alterne d'activation du complément

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731336A (en) * 1982-06-14 1988-03-15 Amersham International Plc Immunoassay for complement fragments
US4624482A (en) * 1984-07-13 1986-11-25 Cassells Wayne R Elongated sheet of material
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4722890A (en) * 1985-08-27 1988-02-02 The United States Of America As Represented By The Department Of Health And Human Services Quantitative assay for human terminal complement cascade activation
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5650389A (en) * 1993-03-01 1997-07-22 University Of Alabama At Birmingham Research Foundation Methods for the inhibition of complement activation
US5679582A (en) * 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5585277A (en) * 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5635493A (en) * 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US6087120A (en) * 1996-02-02 2000-07-11 Haemoprobe B.V. Measurement of complement activation by biomaterials by means of complement convertase cleavage of peptide substrates
JP2000505068A (ja) * 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
US6020141A (en) * 1996-05-09 2000-02-01 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization
CA2217322C (fr) * 1996-10-03 2005-01-04 Coastside Bio Resources Inhibition de la voie d'activation du complement au moyen de fractions de holothuries
EP1007092B1 (fr) * 1997-08-26 2006-08-09 Amgen Fremont Inc. Procede d'inhibition d'activation de complement par la voie alterne
WO1999044625A1 (fr) * 1998-03-03 1999-09-10 John Hopkins University Inhibiteur d'enzymes de complement, derive du virus de la variole (spice), proteines liees au spice et methode d'inhibition de l'activation du complement
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6232296B1 (en) * 1999-09-30 2001-05-15 Isis Pharmaceuticals, Inc. Inhibition of complement activation and complement modulation by use of modified oligonucleotides
EP2113516B1 (fr) * 2000-10-10 2014-05-21 Genentech, Inc. Anticorps contre C5 inhibant l'activation de type II des cellules endothéliales
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOVACS L. ET AL: "Antineutrophil cytoolasmic antibodies and other immunologic abnormalities in patients with habitual abortion", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 41, no. 4, April 1999 (1999-04-01), pages 264 - 270, XP008047348 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465737B2 (en) 2001-04-11 2013-06-18 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US8007804B2 (en) 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US8652475B2 (en) 2004-02-10 2014-02-18 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
US8703140B2 (en) 2004-02-10 2014-04-22 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US8569225B2 (en) 2006-06-21 2013-10-29 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
US7964705B2 (en) 2007-03-14 2011-06-21 Taligen Therapeutics, Inc. Humaneered anti-factor B antibody
US9096677B2 (en) 2007-03-14 2015-08-04 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody

Also Published As

Publication number Publication date
US20070123466A1 (en) 2007-05-31
WO2004103288A2 (fr) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2005011586A3 (fr) Traitement et prevention d'accidents cardiovasculaires
WO2001076573A3 (fr) Combinaison de composés organiques
AU2003294290A1 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
IL245462A0 (en) Antagonists of human origin against cmet
WO2006071274A3 (fr) Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
WO2005112980A3 (fr) Administration renale locale bilaterale pour le traitement de l'insuffisance cardiaque congestive et la therapie aux peptides natriuretiques de type b
WO2005123128A3 (fr) Procedes de traitement d'etats pathologiques associes a l'activation du complement dependante de masp-2
WO2003049675A3 (fr) Traitement de l'amyotrophie a l'aide de modulateurs selectifs du recepteur d'androgene
WO2001037785A3 (fr) Nouveaux procedes et nouvelles compositions comprenant des opioides et des antagonistes d'opioides
IL152573A0 (en) Transdermal delivery system for anti-emetic medication
WO2003075841A3 (fr) Combinaison de procedes d'inhibition de croissance tumorale a l'aide d'un antagoniste du recepteur du facteur de croissance endotheliale vasculaire
WO2004062624A3 (fr) Methode pour traiter des nausees, des vomissements, des haut-le-coeur ou une association de ces symptomes
WO2004000354A3 (fr) Procede de traitement du syndrome de la lipodystrophie
WO2005000194A3 (fr) Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
WO2005007141A3 (fr) Inhibiteurs de l'ubiquitine ligase et methodes associees
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2002043807A3 (fr) Combinaison de composants organiques
WO2006018024A3 (fr) Compositions cosmetiques et pharmaceutiques contenant des inhibiteurs de l'eca et/ou des antagonistes des recepteurs de l'angiotensine ii
WO2004039247A3 (fr) Preparations analgesiques et methodes associees
EP1501426A4 (fr) Systemes, procedes et compostions permettant d'obturer les sites de perforation vasculaires
WO2004062623A3 (fr) Methode de traitement de troubles intestinaux fonctionnels
WO2002072021A3 (fr) Agents et procedes pour la prevention de l'apparition initiale ou de la recurrence des cancers existants
WO2006060787A3 (fr) Retardement ou prevention de l'apparition d'une sclerose en plaques
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
WO2003097086A3 (fr) Antagonistes de recepteur d'egf dans le traitement du cancer gastrique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007123466

Country of ref document: US

Ref document number: 10556493

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10556493

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11888997

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11843617

Country of ref document: US